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Abstract
Idiopathic inflammatory bowel disease (IBD) pre-
dominantly includes ulcerative colitis and Crohn’s 
disease. The pathogenesis of IBD is complex and not 
completely understood. MicroRNAs belong to a class 
of noncoding small RNAs that post-transcriptionally 
regulate gene expression. Unique microRNA expression 
profiles have been explored in IBD. In this review, we 
focus on the unique microRNA expression pattern in 
both tissue and peripheral blood from IBD patients and 
emphasize the potential diagnostic and therapeutic 
applications. The discovery of microRNAs has contri-
buted to our understanding of IBD pathogenesis and 
might lead to clinical advance in new therapeutics.
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of noncoding small RNAs that post-transcriptionally 
regulate gene expression. Unique microRNA expression 
profiles have been explored in IBD. In this review, we 
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applications. The discovery of microRNAs has contri-
buted to our understanding of IBD pathogenesis and 
might lead to clinical advance in new therapeutics.
Fisher K, Lin J. MicroRNA in inflammatory bowel disease: 
Translational research and clinical implication. World J 
Gastroenterol 2015; 21(43): 12274-12282  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v21/i43/12274.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v21.i43.12274
TOPIC HIGHLIGHT
2015 Advances in Inflammatory Bowel Disease
MicroRNA in inflammatory bowel disease: Translational 
research and clinical implication
Kurt Fisher, Jingmei Lin
Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.3748/wjg.v21.i43.12274
World J Gastroenterol  2015 November 21; 21(43): 12274-12282
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
© 2015 Baishideng Publishing Group Inc. All rights reserved.
Fisher K et al . microRNA in inflammatory bowel disease
12275 November 21, 2015|Volume 21|Issue 43|WJG|www.wjgnet.com
INTRODUCTION
Idiopathic inflammatory bowel disease (IBD) predo­
minantly includes ulcerative colitis (UC) and Crohn’s disease 
(CD), which is a chronic and recurrent inflammatory 
disorder primarily involving the gastrointestinal tract. 
The pathogenesis of IBD is multifactorial and not 
completely understood, but genetic, epigenetic, infec­
tious, physiological, and immunological factors may all 
play important roles in the genesis and progression of 
the diseases[1­3]. So far, IBD is generally accepted as a 
complicated consequence attributable to inadequate 
immunological responses to luminal factors in gene­
tically predisposed subjects.
MicroRNAs are encoded within the genomes of a 
wide variety of eukaryotes, including more than 700 
different microRNA genes in the human genome[4,5]. 
MicroRNAs are evolutionarily conserved, single­
stranded non­coding RNA molecules of 19­24 nucle­
otides, which represent a class of regulatory RNAs 
that decrease stability and suppress gene expression 
at a post­transcriptional level. MicroRNAs concurrently 
modulate the expression levels of dozens or more 
distinct messenger RNA (mRNA) targets. Alternatively, 
any given mRNA sequence may be targeted by several 
different microRNAs[4­6]. To date, they have been 
predicted to target and control the expression of at 
least 30% of the entire mammalian genome[7]. Since 
their discovery in 1933, microRNAs have been found to 
be involved in multiple pathophysiological networks[8,9] 
and in the pathogenesis of a broad­spectrum of human 
diseases, including cancer and inflammation[10­15]. Given 
their potential as therapeutic targets, microRNAs have 
drawn a lot of attention recently.
Knowledge of microRNA in IBD has accumulated in 
the past seven years and has indicated that microRNAs 
play critical roles in the pathogenesis of chronic inflam­
mation and oncogenic transformation. Herein, the 
review focuses on the current understanding of micro­
RNA as biomarkers of pathogenesis and potential 
therapeutic implication in IBD.
DYSREGULATED MICRORNAS IN IBD
Multiple studies have demonstrated distinct microRNA 
expression profiles in tissue and peripheral blood of 
IBD patients. Many studies have been conducted on 
tissue and serum of patients with active or inactive 
IBD in an attempt to identify biomarkers and drivers of 
pathogenesis.
Aberrant microRNA profiles in mucosal tissue of UC
Since 2008, dysregulated microRNAs have been 
identified by examining inflamed or uninflamed 
colonic tissue in UC patients[16­25]. As listed in Table 
1, comparing to normal healthy controls aberrantly 
elevated microRNAs have been found including miR­7, 
miR­16, miR­20b, miR­21, miR­23a, miR­24, miR­29a, 
miR­29b, miR­31, miR­98, miR­125b­1*, miR­126, 
miR­126*, miR­127­3p, miR­135b, miR­146a, 
miR­150, miR­155, miR­195, miR­196a, miR­206, 
miR­223, miR­324­3p, miR­375, miR­422b, miR­548a­
3p, miR­650, miR­663, miR­let­7e*, and miR­let­7f. 
The decreased microRNAs include miR­143, miR­145, 
miR­188­5p, miR­192, miR­194b, miR­196b, miR­215, 
miR­216b, miR­320a, miR­346, miR­375, miR­489, 
miR­548e, miR­559, and miR­630.
Given the variable anatomic location of colonic 
tissue, the diverse inflammatory status (either 
inflamed or uninflamed with or without treatment), 
the different cohorts of healthy control and analytical 
systems, it is not surprising that the findings are 
not consistent among researchers. However, three 
microRNA candidates, miR­21[16­18,24], miR­29a[16,19] and 
miR­31[19,23], have been found aberrantly elevated by 
at least two independent groups.
Aberrant microRNA profiles in mucosal tissue of CD
As shown in Table 2, distinct microRNA expression 
profiles have also been studied in patients with 
CD[19,23,25­29]. MiR­9, miR­9*, miR­16, miR­21, miR­22, 
miR­23b, miR­26a, miR­29b, miR­29c, miR­30a, 
miR­30b, miR­30c, miR­31, miR­34c­5p, miR­106a, 
miR­126, miR­126*, miR­127­3p, miR­130a, miR­
133b, miR­141, miR­146a, miR­146b­5p, miR­150, 
miR­155, miR­181c, miR­191, miR­196, miR­196a, 
miR­206, miR­223, miR­324­3p, miR­375, miR­594 
and miR­663 have been found significantly increased 
comparing to the normal controls[19,23,26,28,29]. The 
decreased microRNAs include miR­7, miR­18a*, miR­
19b, miR140­3p, miR­194b, miR­216b, miR­548e, 
miR­559, miR­629, miR­629*, and miR­let­7b[23,27,30].
Among them, miR­21[19,26], miR­31[19,23,29], miR­
106a[19,26], miR­146a[19,23], and miR­223[19,26] have 
been found dysregulated by at least two independent 
groups.
Aberrant microRNA in peripheral blood of UC
As summarized in Table 3, microRNA expression is 
also altered in the peripheral blood in patients with 
UC[24,25,31­34]. In studies examining microRNAs in 
peripheral blood mononuclear cells of patients with 
either active or inactive UC, miR­15b, miR­16, miR­
19a, miR­20b*, miR­21, miR­22, miR­24, miR­27a, 
miR­27a*, miR­28­3p, miR­28­5p, miR­29a, miR­30e, 
miR­31, miR­92a­1*, miR­93, miR­103, miR­103­2, 
miR­103­2*, miR­128, miR­138, miR­140­3p, miR­
142­5p, miR­143*, miR­146a­3p, miR­150*, miR­
151­5p, miR­155, miR­181b, miR­188­5p, miR­196b, 
miR­199a­3p, miR­199a­5p, miR­221, miR­223, miR­
330­3p, miR­340*, miR­345, miR­362­3p, miR­362­
5p, miR­374b, miR­378, miR­378*, miR­422a, miR­
423­5p, miR­500, miR­501­5p, miR­532­3p, miR­
532­5p, miR­550*, miR­598, miR­720, miR­760, 
miR­769­3p, miR­769­5p, miR­874, miR­941, 
miR­1271, miR­1274b, miR­1296, miR­let­7d, miR­
Table 2  Aberrant microRNA expression in human colonic tissue in Crohn’s disease
Table 1  Aberrant microRNA expression in human colonic tissue in ulcerative colitis
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let­7e, miR­let­7g, miR­let­7i*, and miR­plus­E1271 
are increasingly expressed comparing to the normal 
population[24,25,31­34]. The decreased profiles include 
miR­150 and miR­505* comparing to the normal 
controls[25,31,33].
Among them, nine microRNAs, miR­21[24,32], miR­
28­5p[31,32], miR­151­5p[31,32], miR­199a­5p[31,32], 
miR­345[25,34], miR­362­3p[31,33], miR­505*[31,33], miR­532­
3p[31,33] and miR­532­5p[25,34], have been recognized by at 
least two independent groups.
Aberrant microRNA in peripheral blood of CD
As listed in Table 4, altered microRNA expression 
profiles are also found in the peripheral blood in 
patients with CD[25,31­33]. Compared to healthy controls, 
the increased microRNA profiles in the serum of 
patients with active CD include miR­16, miR­20a, 
miR­21, miR­23a, miR­27a*, miR­29a, miR­30e, 
miR­93, miR­106a, miR­107, miR­126, miR­140, miR­
140­3p, miR­140­5p, miR­188­5p, miR­191, miR­192, 
miR­195, miR­199a­5p, miR­200c, miR­340*, miR­362­
3p, miR­484, miR­532­3p, miR­877, miR­plus­E1271, 
and miR­let­7b. The significantly decreased microRNAs 
consist of miR­18a, miR­128, miR­140­5p, miR­145, 
miR­149*, miR­877, and miR­plus­F1065.
Among them, six microRNAs, including miR­16[25,32,33], 
miR­106a[32,33], miR­195[25,33], miR­199a­5p[31,32], miR­
362­3p[31,32], and miR­532­3p[31,32], have been found by 
at least two independent groups.
MicroRNA as a differential biomarker to distinguish 
between UC and CD
As shown in Table 5, studies have shown that micro­
RNAs are differentially expressed between UC and 
CD[19,31,35]. The panel of microRNAs that have been 
found differentially expressed in colonic tissue includes 
Status Tissue type Control Aberrant microRNA expression Ref.
Active UC Sigmoid, n = 15 Healthy Decreased: miR-192 and 375 Wu et al[16], 2008
Increased: miR-16, 21, 23a, 24, 29a, 126, 195, 422b and let-7f
Sigmoid, n = 12 Healthy Increased: miR-21 and 155 Takagi et al[17], 2010
Sigmoid, n = 12 Healthy Increased: miR-21 and 126 Feng et al[18], 2012
Colon, nonspecific, n = 10 Healthy Decreased: miR-188-5p, 215, 320a and 346 Fasseu et al[19], 2010
Increased: miR-7, 31, 135b and 223
Colon, nonspecific, n = 5 Healthy Increased: miR-150 Bian et al[20], 2011
Colon, nonspecific, n = 8 Healthy Decreased: miR-143 and 145 Pekow et al[21], 2012
Colon, nonspecific, n = 20 Healthy Increased: miR-20b, 98 and let-7e* Coskun et al[22], 2013
Active or inactive UC Colon, distalmost, n = 10 Healthy Decreased: miR-194b, 216b, 548e and 559 Lin et al[23], 2014
Increased: miR-31, 146a, 206 and 663
Inactive UC Sigmoid, n = 15 Healthy Increased: miR-16, 23a, 24, 29a, 375 and 422b Wu et al[16], 2008
Colon, nonspecific, n = 8 Healthy Decreased: miR-188-5p, 215, 320a and 346 Fasseu et al[19], 2010
Increased: miR-29a, 29b, 126*, 127-3p, 196a and 324-3p
Colon, nonspecific, n = 19 Healthy Increased: miR-20b and 125b-1* Coskun et al[22], 2013
Unknown Colon, nonspecific, n = 15 Healthy Increased: miR-21 Yang et al[24], 2013
Active UC Colon, nonspecific, n = 20 Inactive UC Increased: miR-98 Coskun et al[22], 2013
Colon, left or sigmoid, n = 9 Inactive UC Decreased: miR-196b, 489 and 630 Iborra et al[25], 2013
Increased: miR-548a-3p and 650
UC: Ulcerative colitis.
Status Tissue type Control Aberrant microRNA expression Ref.
Active CD Sigmoid, n = 5 Healthy Decreased: miR-19b and 629 Wu et al[26], 2010
Increased: miR-23b, 106a and 191
Terminal ileum, n = 6 Healthy Increased: miR-16, 21, 223, and 594 Wu et al[26], 2010
Colon, nonspecific, n = 16 Healthy Increased: miR-9, 21, 22, 26a, 29b, 29c, 30b, 31, 34c-5p, 106a, 126, 126*, 
127-3p, 130a, 133b, 146a, 146b-5p, 150, 155, 181c, 196a, 324-3p and 375
Fasseu et al[19], 2010
Colon, nonspecific, n = 8 Healthy Decreased: miR-7 Nguyen et al[27], 2010
Colon, nonspecific, n = 120 Healthy Increased: miR-196 Brest et al[28], 2011
Active and 
inactive CD
Colon, nonspecific, n = 15 Healthy Increased: miR-31 and 141 Huang et al[29], 2015
Colon, distalmost, n = 9 Healthy Decreased: miR-194b, 216b, 548e and 559
Increased: miR-31, 146a, 206 and 663
Lin et al[23], 2014
Inactive CD Colon, nonspecific, n = 8 Healthy Increased: miR-9*, 21, 22, 26a, 29b, 29c, 30a*, 30b, 30c, 31, 34c-5p, 106a, 
126*, 127-3p, 133b, 146a, 146b-5p, 150, 155, 196a, 223 and 324-3p
Fasseu et al[19], 2010
Active CD Colon, left or sigmoid, n = 9 Inactive CD Decreased: miR-18a*, 140-3p, 629* and let-7b
Increased: miR-328, 422a and 885-5p
Iborra et al[25], 2013
CD: Crohn’s disease; UC: Ulcerative colitis.
Fisher K et al . microRNA in inflammatory bowel disease
Table 5  Differential microRNA expression between ulcerative colitis and Crohn’s disease 
Table 4  Aberrant microRNA expression in human peripheral blood in Crohn’s disease
Table 3  Aberrant microRNA expression in human peripheral blood in ulcerative colitis 
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miR­19b, miR­23b, miR­100a­3p, miR­100b­5p, miR­
106a, miR­150, miR­191, miR­196b, miR­223, miR­
320a, and miR­629[19,35]. Wu and colleagues found 
three microRNAs (miR­3180­3p, miR­plus­E1035 
and miR­plus­F1159) differentially expressed in the 
peripheral blood between UC and CD[31]. Although at 
least two groups have developed tissue microRNA 
panels that attempted to delineate between UC and 
CD, there is little overlap. Importantly, these studies 
vary in the activity status of IBD during sampling, 
which may explain the differences seen by independent 
groups.
MicroRNA in indeterminate IBD
A diagnosis of idiopathic IBD requires comprehensive 
analysis of clinical, radiographic, endoscopic, surgical, 
and histologic data. While most cases of IBD can be 
specifically classified as either UC or CD, 5%­10% 
of IBD patients bear equivocal features, falling into 
the category of indeterminate colitis[36­38]. The ability 
to better classify cases of indeterminate colitis would 
allow for better clinical and surgical management 
of these patients, especially regarding the choice of 
pouch procedure.
In a study by Lin and colleagues, a panel of miR­
Status Tissue type Control Aberrant microRNA expression Ref.
Active UC Peripheral blood, n = 13 Healthy Decreased: miR-505* Wu et al[31], 2011
Increased: miR-28-5p, 103-2*,151-5p, 199a-5p, 340*, 362-3p, 532-3p and 
plus-E1271
Peripheral blood, n = 88 Healthy Increased: miR-16, 21, 28-5p, 151-5p, 155 and 199a-5p Paraskevi et al[32], 2012
Active and 
inactive UC
Peripheral blood, n = 18 Healthy Decreased: miR-150
Increased: miR-15b, 19a, 24, 27a, 28-3p, 29a, 30e, 93, 103, 128, 142-5p, 196b, 
199a-3p, 221, 223, 345, 374b, 423-5P, 532-5p, 598, 760, let-7d, let-7e and let-7g
Iborra et al[25], 2013
Inactive UC Peripheral blood, n = 13 Healthy Decreased: miR-505* Zahm et al[33], 2011
Increased: miR-103-2, 362-3p and 532-3p
Inactive UC Peripheral blood, n = 10 Healthy Decreased: miR-505* Wu et al[31], 2011
Increased: miR-103-2*, 362-3p and 532-3p
Unknown Peripheral blood, n = 20 Healthy Increased: miR-20b*, 22, 27a*, 31, 92a-1*, 138, 140-3p, 143*, 146a-3p, 
150*,181b, 188-5p, 330-3p, 362-5p, 345, 378, 378*,422a, 500, 501-5p, 532-5p, 
550*, 720, 769-3p, 769-5p, 874, 941, 1271, 1274b, 1296 and let-7i*
Duttagupta et al[34], 2012
Peripheral blood, n = 15 Healthy Increased: miR-21 Yang et al[24], 2013
UC: Ulcerative colitis.
Status Tissue type Control Aberrant microRNA expression Ref.
Active CD Peripheral blood, n = 14 Healthy Decreased: miR-149* and plus-F1065 Wu et al[31], 2011
Increased: miR-199a-5p, 340*, 362-3p, 532-3p and plus-E1271
Peripheral blood, n = 46 Healthy Increased: miR-16, 20a, 21, 30e, 93, 106a, 140, 192, 195, 484 and let-7b Zahm et al[33], 2011
Peripheral blood, n = 128 Healthy Increased: miR-16, 23a, 29a, 106a, 107, 126, 191, 199a-5p, 200c, 362-3p 
and 532-3p
Paraskevi et al[32], 2012
Active and 
inactive CD
Peripheral blood, n = 18 Healthy Decreased: miR-877 Iborra et al[25], 2013
Increased: miR-16, 27a*, 140-3p, 140-5p and 195
Inactive CD Peripheral blood, n = 5 Healthy Decreased: miR-149* Wu et al[31], 2011
Increased: miR-340*
Active CD Peripheral blood, n = 9 Inactive CD Decreased: miR-18a, 128, 140-5p and 145 Iborra et al[25], 2013
Increased: miR-188-5p and 877
CD: Crohn’s disease; UC: Ulcerative colitis.
Status Tissue type Control Aberrant microRNA expression Ref.
Inactive UC Colon, nonspecific, n = 8 Inactive CD Decreased: miR-100a-3p, 100b-5p, 150, 196b, 223 and 320a Fasseu et al[19], 2010
Active or inactive UC Colon, distalmost, n = 12 Active or 
Inactive CD
Increased: miR-19b, 23b, 106a, 191 and 629 Lin et al[35], 2013
Active UC Peripheral blood, n = 13 Active CD Increased: miR-3180-3p, plus-E1035 and plus-F1159 Wu et al[31], 2011
CD: Crohn’s disease; UC: Ulcerative colitis.
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19b, miR­23b, miR­106a, miR­191 and miR­629, 
was evaluated in 16 patients with clinical diagnosis 
of indeterminate colitis. They found that 15 patients 
demonstrated UC­like and one CD­like microRNA 
expression patterns[35]. They concluded that microRNA 
expression pattern in indeterminate colitis are far more 
similar to those of UC than CD. The study of microRNA 
expression pattern in indeterminate colitis provides 
molecular evidence indicating that most indeterminate 
colitis are probably UC, rather than CD, which is 
similar to the data from long­term clinical follow­
ups. Molecular testing using microRNA as promising 
markers to improve the classification of indeterminate 
IBD has the considerable advantage of being testable 
at the time of colectomy for improved pouch surgery 
selection. Before being used as a clinically validate test, 
clinical validation in large samples of indeterminate 
colitis patients, especially with correlation to pouch 
prognosis, is a necessity.
MICRORNA AS A POTENTIAL DRIVER OF 
PATHOGENESIS
Despite the heterogeneity of microRNAs identified 
as deregulated in IBD, a few microRNAs confirm in 
multiple studies and may represent causative agents in 
disease development. Here we focus on the microRNA 
with the best evidence as driver of pathogenesis.
MiR-21 potentiates disease severity in IBD
As discussed above, miR­21 has been identified as 
being upregulated in active UC and CD, consistent 
with its possible role in the pathogenesis of IBD[16­18,24]. 
In vitro experiments have shown that the genetic 
deletion of DNMT1 and DNMT3b caused dysregulation 
of approximately 10% of microRNAs, demonstrating 
tight regulation by DNA methylation[39]. The use of 
microarray and confirmatory pyrosequencing have 
shown the miR­21 locus is hypomethylated, and 
therefore overexpressed, in samples of peripheral 
blood in active CD in pediatric and adult patients[40]. 
To determine if miR­21 was a potential driver of IBD 
pathogenesis, a miR­21 knockout mouse model was 
developed and treated with dextran sodium sulphate 
(DSS) to induce a chronic colitis model with an 
elevation of tumor necrosis factor alpha (TNF­α) that 
mimics human IBD[41]. In wild type mice, the addition 
of DSS caused a significant increase in miR­21 levels, a 
dramatic reduction in weight, and significant mortality 
while the miR­21 knockout mice were resistant to 
these negative effects, which supports a role of miR­21 
in IBD pathogenesis.
The pathogenic effects of miR­21 overexpressing 
are thought to be mediated through at least 3 separate 
mechanisms. First, miR­21 is thought to cause 
increased intestinal permeability, a factor thought to 
initiate IBD. At baseline, no difference in intestinal 
permeability was seen between wild type and miR­21 
knockout mice[41]. After treatment with DSS, intestinal 
permeability was greater in wild type mice than that 
of miR­21 knockout strain. Secondly, miR­21 is pro­
apoptotic. Although the mechanism has not been 
elucidated, miR­21 knockout mice treated with DSS 
had less intestinal epithelial cell apoptosis[41]. Prevention 
of epithelial cell apoptosis may help maintain the 
epithelial cell barrier and limit inflammation and 
disease progression. Thirdly, interstitial fibrosis is a 
hallmark of IBD and miR­21 has been associated with 
fibrosis in multiple disease models. Mouse models of 
renal fibrosis have shown that cellular injury leads to 
increased levels of TNF­α and subsequent induction 
of miR­21[42]. Inhibition of miR­21 prevented fibrosis, 
presumably through preventing the recruitment of 
pro­fibrotic inflammatory cells[42]. Increased serum 
levels of miR­21 were seen in humans with idiopathic 
pulmonary fibrosis and may serve as a non­invasive 
biomarker for disease progression[43]. Analysis of 
serum and hepatic tissue from patients with cirrhosis 
has also shown that increased miR­21 levels are 
associated with levels of fibrosis[44]. Although miR­21 
has not been experimentally linked to fibrosis in IBD 
yet, its role deserves further study. Interestingly, 
miR­21 expression was found to be high in IBD­
associated dysplasia suggesting that its expression is 
maintained throughout the development of dysplasia 
and carcinogenesis, but more controlled studies are 
needed to define its role[45].
MICRORNA AS A POTENTIAL 
BIOMARKER FOR CARCINOGENESIS
Longstanding IBD is a well­known risk factor for 
colorectal cancer, although mechanisms of carcino­
genesis are poorly unknown[46,47]. Studies have shown 
that the risk of IBD­associated colon cancer is related 
to the extent of the disease, severity of inflammation, 
and duration[48­50]. With chronic inflammation, colonic 
epithelium undergoes a transformation from inflamed, 
but not dysplastic to progressively dysplastic, and 
eventually to adenocarcinoma. Colonoscopies with 
surveillance biopsies for IBD­associated dysplasia 
are used to help guide surgical timing of colectomies. 
Although histologic examination can reproducibly 
identify dysplasia, IBD­associated dysplasia cannot 
be distinguished from sporadic dysplasia based on 
histologic appearance alone. Histologic examination 
of IBD­associated adenocarcinomas has characteristic 
features and demographics which may indicate a 
specific pathway to carcinogenesis[51]. Molecular 
alterations have been shown to lead to this histological 
progression[52­58]. Previous studies have demonstrated 
molecular abnormalities in normal­appearing non­
dysplastic mucosa from patients with UC who had 
a remote dysplastic lesion[55­57,59­61]. Aneuploidy, 
chromosomal alterations, p53 mutation, loss of hetero­
zygosity, and chromosome instability are present in 
Fisher K et al . microRNA in inflammatory bowel disease
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normal­appearing mucosa before the development of 
dysplasia[55­57,59­61].
Studies of microRNAs may elucidate distinct 
pathways that may help reliably identified IBD­
associated dysplasia and subsequent carcinogenesis. 
Recent studies demonstrate that microRNAs are 
largely involved in oncogenesis via their regulation 
of tumor suppressors and oncogenes[62]. In a study 
by Olaru et al[63], microRNA arrays were performed 
on tissue from eight patients with IBD­associated 
dysplasia. Twenty two microRNAs (miR­31, miR­31*, 
miR­96, miR­135b, miR­141, miR­183, miR­192, 
miR­192*, miR­194, miR­194*, miR­200a, miR­
200a*, miR­200b, miR­200b*, miR­200c, miR­203, 
miR­215, miR­224, miR­375, miR­424*, miR­429, 
and miR­552) were significantly upregulated and 10 
microRNAs (miR­122, miR­139­5p, miR­142­3p, miR­
146b­5p, miR­155, miR­223, miR­490­2p, miR­501­
5p, miR­892b, and miR­1288) were downregulated in 
dysplastic epithelium compared to the non­dysplastic 
inflamed tissue.
MiR-31 identifies IBD-associated dysplasia
MiR­31 is upregulated in UC and CD, but not in other 
non­IBD colitis, such as microscopic colitis, that have 
no association with dysplasia or malignancy[64]. As 
early as 2007, miR­31 was found to be upregulated in 
sporadic colorectal adenocarcinomas[65­67]. However, 
the role of miR­31 in IBD­associated dysplasia or 
malignancy has only recently been examined. An 
assessment of the baseline miR­31 expression in 
normal tissue regardless the different anatomic 
locations of the colon allows for comparison of all 
colon specimens equally[63]. In addition, no difference 
of miR­31 expression level was seen between IBD­
associated dysplasia and IBD­associated carcinomas. 
Importantly, the levels of miR­31 were found 11­fold 
higher in IBD­associated dysplasia or carcinoma when 
compared to that of IBD tissue without dysplasia[63]. 
Although in a smaller study set, these findings were 
not replicated and a link between microRNAs and p53 
dysregulation was indicated[68] Taken together, these 
findings suggest that miR­31 alteration might happen 
early in carcinogenesis and may be used a biomarker 
for IBD­associated dysplasia or malignancy.
MICRORNA AS POTENTIAL 
THERAPEUTIC TARGETS FOR IBD
Understanding the underlying mechanisms that 
regulate gene expression and the complex interplay 
of factors is essential to develop novel therapeutics 
in IBD. The post­transcriptional regulation of gene 
expression is unique and is becoming increasingly 
important.
The ability of microRNAs to target multiple genes 
and biological signaling pathways has drawn great 
attention in potential clinical utility as innovative 
therapeutic agents in treatment. Antisense oligo­
nucleotides complementary to microRNAs, namely 
anti­microRNA oligonucleotides, can target specific 
microRNAs abolishing their function in in vitro cultured 
cells, or in vivo in animal models. For example in the 
achievement of cancer research, recent accumulating 
preclinical studies have shown the feasibility of 
slowing tumor progression by either overexpressing 
tumor suppressive microRNAs, or by neutralizing the 
activities of oncogenic microRNAs in cell­ or animal­
based cancer models[69­72]. In addition, a number of 
clinical drugs have shown to modulate the microRNA 
expression as anticancer effect in vitro[73,74].
Particularly in the field of IBD, the mechanisms to 
modify microRNAs that might activate or inactivate 
pathways required for the inflammation progress are 
worth investigating. Potential therapeutic application 
targeted on microRNA is to block inflammatory 
progression to improve sensitivity to conventional 
therapies. The pharmacologic targeted tissue delivery 
consists of two general strategies: (1) antisense 
oligonucleotides complementary to specific mature 
microRNAs to inactivate the overexpressed pro­
inflammatory process; and (2) to replace the expression 
of suppressive microRNAs.
To date, no therapeutic manipulation of microRNAs 
in IBD has been published in either cell lines or animal 
models yet. Although recent study has shown that 
inhibition of miR­21, a promising pathogenetic driver 
in IBD, slows the proliferation and progression in a 
nasopharyngeal carcinoma cell line[75]. The similar 
approach is expected to be tested in IBD cell line 
or animal model. Although side effects are another 
essential issue to be considered before an effective 
drug enters the markets, we can’t help speculating 
that a new therapeutic concept, targeted microRNA 
drug for IBD, maybe emerges in the near future.
DILEMMAS
During the past 7 years, the identification of microRNA 
in IBD has broadened our knowledge. However, 
the lack of a standardized approach often leads to 
inconsistent or even conflicting results.
The nomenclature for microRNA has continued to 
evolve since its discovery in 1993[8,9]. MicroRNAs were 
named in the order they were discovered, leading to 
identical microRNAs being given different names by 
different groups. As the microRNA field continues to 
expand, significant efforts have been made to clarify 
nomenclature using a unified system. Recent data 
added from deep genome sequencing has pushed the 
number of annotated microRNAs to roughly 1900 in 
the most recently nomenclature database, miRBase 
version 21[76]. The complicated historical nomenclature 
of microRNA makes literature evaluation difficult and 
diligent effort to confirm sequence identity of each in 
the literature must be made.
One of the most commonly encountered problems 
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is when we attempt to verify microRNA’s role in IBD 
pathogenesis. Recent developments in microarrays 
have led to numerous attempts to identify microRNAs 
associated with a diverse set of disease processes. 
Despite the ability of candidate microRNAs to be 
validated by additional RT­PCR, there has been little 
reproducibility between groups. Differences in samples 
obtained from various anatomic locations, treatment 
regimens, and activity level of disease may account 
for discrepancies seen between studies. Additionally, 
microRNAs with the same sequence identity are given 
modifiers in their name based on their location within 
the genome. Most techniques do not distinguish 
microRNAs that have the same sequence but at 
different locations in the genome[76]. A more clear 
understanding of the genetic loci associated with micro­
RNAs can provide insight into how they are regulated 
and become deregulated in pathogenesis.
CONCLUSION
In summary, the accumulating knowledge of microRNA 
has significantly expanded our understanding of 
the pathogenesis of IBD and has demonstrated the 
usefulness of microRNAs as biomarkers with emerging 
clinical utility and the potential for personalized 
therapies.
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